In vitro and in vivo antibacterial activities of TOC-50, a new parenteral cephalosporin, against Enterococcus faecalis.
In vitro and in vivo antibacterial activities of TOC-50, a new parenteral cephalosporin, were assessed against Enterococcus faecalis. In vitro, TOC-50 had excellent activity, stronger than that of penicillin G, sulbactam/ampicillin, tazobactam/piperacillin, the cephalosporins tested, imipenem, vancomycin, gentamicin, tobramycin, arbekacin, amikacin, minocycline and ofloxacin against clinically isolated strains. In addition, TOC-50 was more active than penicillin G, sulbactam/ampicillin and imipenem against vancomycin-resistant E. faecalis NCTC 12201. In terms of bactericidal effect against the same strain, TOC-50 was superior to sulbactam/ampicillin and imipenem. In murine systemic infection models, TOC-50 had a potent protective activity against E. faecalis 42. Its protective activity was stronger than that of imipenem or vancomycin.
Nomura
S
S
Anticancer and Antimicrobial Research Laboratory, Taiho Pharmaceutical Company, Japan.
Hanaki
H
H
Furukawa
T
T
Unemi
N
N
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D013293:Enterococcus faecalis / Q000187:drug effects*; D015378:Imipenem / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C103730:TOC 50; D014640:Vancomycin; D015378:Imipenem